Exploring New Frontiers in the Management of Osteoporosis
Release date: May 2009
Expiration date: May 31, 2010
Estimated time to complete activity: 1.75 hours
Sponsored by
Support for this activity has been provided through an educational donation from
Activity Overview
This CME/CE-certified Web-based enduring activity is based on information presented at a satellite symposium held on April 3, 2009 in Washington, DC during the 8th Annual International Symposium on Osteoporosis (ISO).
Target Audience
This activity has been designed to meet the educational needs of health care professionals in endocrinology, rheumatology, bone disease, obstetrics/gynecology, and primary care, who manage patients who have or are at risk for osteoporosis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe mechanisms of therapeutic intervention based on the cellular and molecular pathways involved in the pathophysiology of osteoporosis
- Evaluate the latest clinical safety and efficacy data for new therapeutic agents for osteoporosis
- Identify factors to consider in patient selection for osteoporosis therapies
- Assess specific risks for osteoporosis and osteoporosis-related fractures, including secondary causes
- Formulate patient management strategies based on individual risk for osteoporosis and osteoporosis-related fractures
Faculty
Susan L. Greenspan, MD—Chair
Professor of Medicine
Director, Osteoporosis Prevention and Treatment Center
University of Pittsburgh Medical School
Pittsburgh, Pennsylvania
Brendan Boyce, MD
Professor of Pathology and Laboratory Medicine
Professor of Orthopedics
The University of Rochester Medical Center
Rochester, New York
Paul D. Miller, MD
Distinguished Clinical Professor of Medicine
University of Colorado Health Sciences Center
Denver, Colorado
Medical Director
Colorado Center for Bone Research
Lakewood, Colorado
Kenneth G. Saag, MD
Associate Professor of Medicine
Division of Clinical Immunology and Rheumatology
University of Alabama
Birmingham, Alabama
Accreditation Statement/Credit Designation
Physician:
Curatio CME Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Curatio CME Institute designates this educational activity for a maximum of 1.75 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nursing:
EduPro Resources LLC is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center (ANCC)’s Commission on Accreditation, Provider Number P208-8/08-11.
EduPro is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-14387.
This activity is approved for 1.75 nursing contact hours.
Participants should not claim credit for this activity if credit was previously claimed for the symposium on which this internet activity is based.
Method of Participation
There are no fees for participating in this CME activity. To receive credit during the period May 2009 to May 31, 2010, participants must (1) read the learning objectives and disclosure statements, (2) study the entire educational activity, (3) complete the presurvey and postsurvey, and (4) complete the activity evaluation form.
The posttest can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.
Media
This activity will be offered as an Internet activity on OsteoporosisTX.com. Offering this CE activity online allows participants to learn on their own time and at their own pace. The interactive nature of the activity allows participants to become engaged and offers visual, written, and spoken education to suit many learning styles.
Disclosure
In accordance with the ACCME and ANCC Standards for Commercial Support, all CME and CNE providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME/CNE activity content over which the individual has control. Relationship information appears below:
Brendan F. Boyce, MD, has disclosed the following relevant financial relationships:
| Consultant | Kinex Pharmaceuticals |
Susan L. Greenspan, MD, has disclosed the following relevant financial relationships:
| Consultant | Merck |
| Research | Eli Lilly, Merck, Novartis, Procter & Gamble Pharmaceuticals, Sanofi-aventis |
Paul D. Miller, MD, has disclosed the following relevant financial relationships:
| Consultant | Amgen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, NPS, Procter & Gamble Pharmaceuticals, Roche, Sanofi-aventis |
| Grants | Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble Pharmaceuticals, Roche, Sanofi-aventis |
Kenneth G. Saag, MD, MSc, has disclosed the following relevant financial relationships:
| Consultant | Amgen, Eli Lilly, Merck, Novartis, Procter & Gamble Pharmaceuticals, Sanofi-aventis, Roche |
| Research | Abbott, Amgen, Centocor, Roche, Wyeth |
| Speaker | Novartis |
Curatio CME Institute
Shari Dermer, PhD, Medical Director, has disclosed no relevant financial relationships.
Thomas Finnegan, PhD, Medical Writer, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial relationships.
Derek Warnick, CME Director, has disclosed no relevant financial relationships.
EduPro Resources LLC
Dorothy Caputo, MA, APRN, BC-ADM, CDE, Nurse Planner, has disclosed no relevant financial relationships.
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient's medical condition.
Accreditation refers to educational content only and does not imply ANCC, CBRN, or EduPro endorsement of any product or service.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, EduPro Resources, and Amgen do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, EduPro Resources LLC, or Amgen Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/ Investigational Use |
| Bazedoxifene | N/A | N/A | Postmenopausal osteoporosis |
| Denosumab | N/A | N/A | Postmenopausal osteoporosis |
| Etidronate | Didronel® | Indicated for the treatment of symptomatic Paget's disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury | Glucocorticoid-induced osteoporosis |
| Lasofoxifene | N/A | N/A | Postmenopausal osteoporosis |
| Odanacatib | N/A | N/A | Postmenopausal osteoporosis |
| Pamidronate | Aredia® | Indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Indicated for the treatment of patients with moderate to severe Paget's disease of bone. Also indicated in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma | Osteoporosis caused by androgen deprivation therapy |
| Teriparatide | Forteo® | Indicated for the treatment of postmenopausal women with osteoporosis who are at high risk for fracture. Also indicated to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture | Glucocorticoid-induced osteoporosis |
Abbreviations
| ALN | alendronate |
| BMD | bone mineral density |
| BMI | body mass index |
| BZA | bazedoxifene |
| CFU-M | macrophage |
| COPD | chronic obstructive pulmonary disease |
| DXA | dual-energy x-ray absorptiometry |
| FRAX | WHO Fracture Risk Assessment Tool |
| GERD | gastroesophageal reflux disease |
| GIOP | glucocorticoid-induced osteoporosis |
| GnRH | gonadotropin-releasing hormone |
| IBD | ibandronate |
| LRP | low-density lipoprotein-like protein |
| LS | lumbar spine |
| NOF | National Osteoporosis Foundation |
| ONJ | osteonecrosis of the jaw |
| OPG | osteoprotegrin |
| OVX | ovariectomy |
| PBO | placebo |
| PMO | postmenopausal osteoporosis |
| PTH | parathyroid hormone |
| PTHrp PTH | parathyroid hormone–related protein |
| RANK | receptor activator of nuclear factor kB |
| RANKL | RANK ligand |
| RIS | risedronate |
| RLX | raloxifene |
| RCT | randomized controlled trial |
| SARM | selective androgen receptor modulator |
| SERM | selective estrogen receptor modulator |
| SMR | standardized mortality ratio |
| SSRI | selective serotonin reuptake inhibitor |
| WHO | World Health Organization |
| TH | total hip |
| ZA | zoledronic acid |
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Contact Information
OsteoporosisTX.com
100 Campbell Boulevard
Suite 103
Exton, PA 19341
OsteoporosisTX@curatiocme.com
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of OsteoporosisTX.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use OsteoporosisTX.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on OsteoporosisTX.com.
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.
Information gathered through OsteoporosisTX.com will not be released to any other company or organization for any purpose; this information remains confidential. At the end of the mandatory 6-year period, these records will be destroyed.
Curatio CME Institute uses Web site tracking software to determine how OsteoporosisTX.com is used. This information helps Curatio CME Institute determine the best strategies for improving OsteoporosisTX.com and better meeting the needs of its users. This software does not identify individual users.
OsteoporosisTX.com does not employ cookies or any other software that violates a user's privacy.
If you have any questions about OsteoporosisTX.com or any Curatio CME Institute policies, you may contact us at OsteoporosisTX@curatiocme.com.
Thank you for using OsteoporosisTX.com
